glucagon like peptide 1 glp 1 agonists Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor A glimpse of the future:
Description
The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke
Explore the differences in GLP-1 patches vs injections and pills
Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director
